AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS
PR Newswire —
PASADENA, Calif., March 10, 2026 /PRNewswire/ -- AcuraStem, a patient-based biotechnology company developing disease-modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting...